---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-100080"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2024-04-18T23:59:59+00:00"
generated_at: "2026-06-03T19:21:24.695934+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days

## Summary
- First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.
- No serious adverse events observed; two subjects had transient Grade 2 GERD that resolved with standard medication.
- BB-301 is a gene therapy for OPMD, affecting ~15,000 patients worldwide; has FDA and EMA Orphan Drug designation.
- Data from 90-day timepoint demonstrated improvement over initial natural history measurements taken >12 months prior.

## SEC filing metadata
- accession: 0001193125-24-100080
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2024-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/0001193125-24-100080-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/d815188d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-100080
- JSON: https://secwatch.observer/filing/0001193125-24-100080.json
- Plain text: https://secwatch.observer/filing/0001193125-24-100080.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.